It is of note that for cancer patients whose tumor expressing MAGEA4 and MHC I, MAGEA4 vaccines can induce MAGEA4-specific immune responses to activate the CD4+ and CD8+ T cell resulting in the inhibition of tumor cell proliferation [63, 64] (Fig. 6f). Here, MAGEA4 is linked to neoplasm.